TherapeuticsMD, Inc.
TXMD Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.80
KIRA · Stoqly’s AI analyst, in plain words
- TherapeuticsMD, Inc. had $3.0M of revenue in fiscal 2025, up 71.6% on the year before. Over five years, revenue changed −45.8% a year on average.
- Its operating margin was −145.3%, up 201.8 pts: of every 100 in sales, about −145 is left after running the business.
- TherapeuticsMD, Inc. lost $0.6M in fiscal 2025.
Market cap
$21.0M
P/E
—
Revenue
$3.0M
Net income
−$0.6M
Free cash flow
—
Operating margin
−145.3%
TherapeuticsMD, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+71.6%
Yes. Sales grew 71.6% last year.
Does it make a profit?
−18.8%
No. It lost money last year.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What TherapeuticsMD, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- TherapeuticsMD, Inc.
- CIK
- 0000025743
TherapeuticsMD, Inc. · TXMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.6M | $70.0M | $1.3M | $1.8M | $3.0M |
| Revenue growth | −96.0% | 2,619.1% | −98.1% | 35.3% | 71.6% |
| Gross margin | 45.5% | 98.0% | 100.0% | — | — |
| Operating margin | −3,092.8% | 1.7% | −654.6% | −347.1% | −145.3% |
| Net income | −$172M | $112M | −$10.3M | −$2.2M | −$0.6M |
| Net margin | −6,700.9% | 160.1% | −789.4% | −123.9% | −18.8% |
| Diluted EPS | −$21.66 | $11.96 | −$0.99 | −$0.19 | −$0.05 |
| Cash | |||||
| Cash from operations | −$143M | $9.4M | −$23.1M | $1.2M | $2.5M |
| Capital expenditure | $0.0M | — | — | — | — |
| Free cash flow | −$143M | — | — | — | — |
| FCF margin | −5,547.1% | — | — | — | — |
| Share count change | −97.1% | 17.7% | −99.9% | 110,784.6% | 0.3% |
| Debt and strength | |||||
| Cash and short-term investments | $64.9M | $49.3M | $4.3M | $5.1M | $7.5M |
| Debt incl. finance leases | $188M | — | — | — | — |
| Shareholders' equity | −$93.6M | $35.1M | $29.3M | $27.4M | $26.9M |
| Current ratio | 0.5x | 1.2x | 1.7x | 2.4x | 3.0x |
| Interest coverage | −2.4x | 6.0x | −28.4x | −611.2x | −548.8x |
| Returns and quality | |||||
| Return on capital | −211.4% | — | — | — | — |
| Return on equity | — | — | −31.9% | −7.7% | −2.1% |
| Return on tangible equity | — | 397.2% | −44.3% | −9.5% | −2.5% |
| Piotroski F-score | 3 | 6 | 3 | 5 | 5 |
| Altman Z'' | −28.9 | −32.5 | −69.9 | −77.3 | −78.9 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TherapeuticsMD, Inc. · TXMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.80 a share, the company is worth $21.0M.
Source: SEC EDGAR XBRL filings (CIK 0000025743). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.